Day 1: Monday, 12 October 2015 (09:00-17:30)
8:00 – 9:00 Registration and Coffee
9:00 – 10:00 Welcome
- Austrian Federal Ministry of Health, Minister Sabine Oberhauser
- Gesundheit Österreich GmbH, General Manager Georg Ziniel
- WHO, Director of the Essential Medicines and Health Products Department Kees de Joncheere
- WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Sabine Vogler
Facilitator: Lena Lepuschütz, GÖG (Austrian Public Health Institute)
10:00 - 10:45 Key Note: Affordable innovation - Future Directions in Pharmaceutical Policy
Suzanne Hill, Senior Adviser, Policy Access and Use, Essential medicines and health products Department, WHO HQ Download
Commentary:
Menno Arnout, AIM/International Association of Mutual Benefit Societies
Valérie Paris, Organisation for Economic Co-operation and Development (OECD), France
Facilitator: Lena Lepuschütz, GÖG (Austrian Public Health Institute)
10:45 - 11:15 Coffee Break
11:15 – 12:15 Stakeholder Roundtable: Pharmaceutical Policies in Crisis? Needs for Change
- Francis Arickx, Social Health Insurance (INAMI), Belgium
- Richard Bergström, European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Tim Reed, Health Action International (HAI) Global
- Jan Mazag, State Institute for Drug Control (SUKL), Slovakia
Commentary:
Pieter Dylst, European Generic and Biosimilar Medicines Association (EGA)
Catherine Day, Irish Pharmacy Union (on behalf of PGEU)
Facilitator: Hans Hogerzeil, University Groningen
12:15 – 12:30 Outlook on Conference
Lena Lepuschütz, GÖG (Austrian Public Health Institute)
12:30 - 14:00 Lunch Break
14:00 – 15:15 Breakout Session 1
Strand I: Challenges and Opportunities for Pharmaceutical Policies
- Key Note: WHO Priority Medicines for Europe and the World: Setting a public-health-based medicines development agenda,
Veronika Wirtz, Boston University, USA Download- Abstract Presentation 1: Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
Elizabeth Docteur, Elizabeth Docteur Consulting, US Download - Abstract Presentation 2: Financial based agreements and performance based agreements: the Belgian experience
Kim Pauwels, KU Leuven, Belgium (Young Researcher Award) Download
- Abstract Presentation 1: Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
Strand II: Policies beyond the Crisis: Lessons Learned
- Key Note: Pharmaceutical Policies in Australia and New Zealand
Zaheer-Ud-Din Babar, University of Auckland, New Zealand Download- Abstract Presentation 1: Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
Juraj Slabý, State Institute for Drug Control, Prague, Czech Republic Download - Abstract Presentation 2: Impact of discounts on medicine prices
Peter Schneider, GÖG (Austrian Public Health Institute), Austria Download
- Abstract Presentation 1: Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
Strand III: Policy Cooperation and Interface Issues
- Key Note: Scottish collaboration to integrate medicine therapy between out-patient and in-patient sectors
Ken Paterson, University of Glasgow, Scotland Download- Abstract Presentation 1: Determinants of differences in utilisation of cancer medicines in Belgium, Scotland and Sweden.
Alessandra Ferrario, London School of Economics (LSE), England - Abstract Presentation 2: A cost/benefit analysis of self-care initiatives in the European Union – who gains, who loses?
Julia Bobek, GÖG (Austrian Public Health Institute), Austria Download
- Abstract Presentation 1: Determinants of differences in utilisation of cancer medicines in Belgium, Scotland and Sweden.
15:15 – 15.45 Poster walk during coffee break
15.45 – 17.00 Moderated Poster Session
Strand I: Challenges and Opportunities for Pharmaceutical Policies
- Poster Presentations
- 1: Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin
Jessica Fraeyman, Department of Epidemiology and Social Medicine, Research Unit of Medical Sociology and Health Policy, University Antwerp, Belgium Download - 2: Impact of Generic Price Linkage System and Reference Price System on Prices of Pharmaceuticals – Comparison of Austria and Finland
Jaana Martikainen, Social Insurance Institution, Finland Download - 3: Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region
Agnes Vitry, University of South Australia, Australia Download - 4: Unintended consequences of pharmaceutical policies: A three country qualitative study of Namibia, South Africa and Ghana insurance reimbursement models
Emmanuel K Eghan, Management Sciences for Health (MSH), Arlington, USA Download
- 1: Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin
Strand II: Policies beyond the Crisis: Lessons Learned
- Poster Presentations
- 1: Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform
Olivier Wouters, London School of Economics (LSE), England Download - 2: Impact of delisting OTC medicines from reimbursement list in Czech Republic
Petra Chytilová, State Institute of Drug Control (SIDC), Czech Republic Download - 3: The impact of Ghana’s National Health Insurance Scheme (NHIS) median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
Dumebi Mordi, Management Sciences for Health (MSH), Arlington, USA Download - 4: The Effect of Pricing Regulation on Prescription Frequency of Compounded Drugs, Medical Foods, and Convenience Packages in the US
Tracy Lin, University of California, USA Download
- 1: Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform
Strand III: Policy Cooperation and Interface Issues
- Poster Presentations
- 1: Retrospective financial analysis of medicines reimbursement services in community pharmacy
Elena Chitan, State University of Medicine and Pharmacy 'Nicolae Testemitanu, Moldova' Download - 2: Multi-Indication Pricing: Pros, Cons and Applicability to the UK
Jorge Mestre-Ferrandiz, Office of Health Economics, England Download - 3: A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results.
Roberta Joppi, Local Health Authority of Verona - Veneto region, Italy Download - 4: Policy options to deal with high-cost medicines – Survey with European policy-makers
Nina Zimmermann, GÖG (Austrian Public Health Institute), Austria Download
- 1: Retrospective financial analysis of medicines reimbursement services in community pharmacy
17.00 – 17.30 Key Note: New WHO Report ‘Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research’
Hanne Bak Pedersen, WHO Regional Office for Europe Download
Facilitator: Aukje Mantel-Teeuwisse, Utrecht University, the Netherlands
17:30 – 18:30 Reception
Day 2: Tuesday 13 October 2015 (09:00 - 15:30)
8:00 - 9:00 Early Bird Session: Meet the Editors
- Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar Download
- PharmacoEconomics, Chris Carswell (online) Download
- Health Policy, Panos Kanavos Download
- Generics and Biosimilars Initiative Journal (GaBI), Arnold Vulto Download
- Bulletin of the World Health Organization, Laragh Gollogly Download
Facilitator: Aukje Mantel-Teeuwisse, Utrecht University
9:00 – 10:00 Country Poster Presentations
European Union/European Economic Area Countries
- Austria: Margit Gombocz, GÖG (Austrian Public Health Institute) and Robert Sauermann, HVB (Main Association of Austrian Social Security Institutions) Download
- Cyprus: Helena Panayiotopoulou, Pharmaceutical Services, Ministry of Health Download
- Ireland: Kate Mulvenna, Health Service Executive Download
- Sweden: Peter Skiöld, The Dental and Pharmceutical Benefits Agency (TLV) Download
Facilitator: Robin Šebesta, State Institute for Drug Control, Czech Republic
Other European Countries
- Norway: Helga Festoy, Norwegian Medicines Agency Download
- Russia: Liudmila Bezmelnitsyna, National Institution for Public Health Download
- Switzerland: Jörg Indermitte, Federal Office of Public Health Download
- Ukraine: Olga Sadovnycha, State Expert Centre of the Ministry of Health Download
Facilitator: Guillaume Dedet, WHO Regional Office for Europe
Non-European Countries
- Canada: Tanya Ptashnik, Patented Medicine Prices Review Board (PMPRB) Download
- Colombia: Angela Acosta Santamaria, Pontificia Universidad Javeriana Download
- Mexico: Yared Santa-Ana-Tellez, Utrecht University, the Netherlands Download
- South Africa: Ntobeko Mpanza, National Department of Health Download
Facilitator: Veronika Wirtz, Boston University, USA
10:00 – 10:30 Poster walk during coffee break
10:30 – 12:00 Breakout Session 2
Strand I: Challenges and Opportunities for Pharmaceutical Policies
- Key Note: Biosimilars – Same quality, lower price, improved patient access
Arnold Vulto, Erasmus University Hospital, Netherlands Download- Abstract Presentation 3: Access to subsidised medicines, cost of medicines and health outcomes: Exploring general practitioners’ perceptions and experiences
Zaheer-Ud-Din Babar, University of Auckland, New Zealand Download - Abstract Presentation 4: Using a Multiple Criteria Decision Analysis (MCDA) framework to make coverage decisions: an experimental case study on metastatic colorectal cancer
Aris Angelis, London School of Economics (LSE), England Download - Abstract Presentation 5: Approval, reimbursement and pricing of high cost cancer medicines in Australia
Agnes Vitry, University of South Australia, Australia Download
- Abstract Presentation 3: Access to subsidised medicines, cost of medicines and health outcomes: Exploring general practitioners’ perceptions and experiences
Strand II: Policies beyond the Crisis: Lessons Learned
- Key Note: The Greek experience – Lessons learned
Panos Kanavos, London School of Economics, UK Download- Abstract Presentation 3: Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
Susan Spillane, National Centre for Pharmacoeconomics, Ireland Download - Abstract Presentation 4: Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
Yared Santa-Ana-Tellez, Utrecht University, the Netherlands Download - Abstract Presentation 5: Socioeconomic Determinants of Medicines Use in Central Eastern Europe: The Role of Pharmaceutical Policy in Reducing Inequalities
Susanne Mayer, Department of Health Economics, Centre for Public Health, Medical University of Vienna, Austria Download
- Abstract Presentation 3: Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
Strand III: Policy Cooperation and Interface Issues
- Key Note: The sofosbuvir case – Lessons learned
Florent Dromzée, Ministry of Health, France Download- Abstract Presentation 3: Why we should have more collaboration on HTA in Europe: The example of sofosbuvir
Wim Goettsch, National Health Care Institute, the Netherlands Download - Abstract Presentation 4 : Criteria for Inclusion into the Essential Medicines List
Nicola Magrini, World Health Organization, Switzerland Download - Abstract Presentation 5: Collaborative models for increasing efficiency of early drug assessment
Anna Nachtnebel, Ludwig Boltzmann Institute for Health Technology Assessment, Austria Download
- Abstract Presentation 3: Why we should have more collaboration on HTA in Europe: The example of sofosbuvir
12:00 – 13:30 Lunch
13:30 – 15:30 Afternoon session
Facilitator: Kees de Joncheere, WHO Headquarter, Switzerland
13:30 - 14:30 Key Note: Perspectives for the Future
Andy Gray, University of KwaZulu-Natal, South Africa Download
14:30 – 15:00 Closing Commentary: Patients have the last word?
Nicola Bedlington, European Patients’ Forum Download
15:00 – 15:30 Conclusions, awards and closure
Sabine Vogler, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Austria